Clay Siegal is the Co-founder and chief executive officer at Seattle Genetics this company was started in 1998 and deals with the cancer research and provide treatment to cancer patients. He is also included as a member of the board of director in three different private Biotech companies, these include; Mirna Therapeutics, Alder Biopharmaceuticals and the Fred Hutchinson Research Center. Dr. Siegal graduated from the University of George Washington having attained a Ph.D. in Genetics. He has led his company to the development of antibody drug conjugates (ADC). In 2011 he got the FDA to approve ADCENTRIS, the first ADC product the company produced. Currently, Adcentris is accepted in over 50 countries worldwide. This drug has been used worldwide as a testing drug to cure the different types of lymphoma
Dr. Siegal has played crucial roles in leading to the creation of agreements and partnerships with other like companies in the same field. He holds 15 patents and has written more than 70 books and publications. His function as a CEO has been very beneficial to the company having secured more than $325 million through public and private financing and getting into business deals of more than $860 million. Dr. Siegal has been very strategic with the management of the Biotech Company. Even after having grown the company tremendously by making large sums of money, the CEO plans to expand the drug pipeline to create more employment and increase the supply of the drugs over the increasing demand.
With his vast knowledge and experience, Dr. Siegal is not merely a regular researcher but a scientist in the making.